Hugues de Boussac
Overview
Explore the profile of Hugues de Boussac including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ovejero S, Alibert L, Devin J, Caneque T, Jacquier V, Romero A, et al.
Theranostics
. 2025 Mar;
15(7):2834-2851.
PMID: 40083931
Mantle-cell lymphoma (MCL) remains an aggressive and incurable cancer. Accumulating evidence reveals that abnormal iron metabolism plays an important role in tumorigenesis and in cancer progression of many tumors. Based...
2.
Bruyer A, Dutrieux L, de Boussac H, Martin T, Chemlal D, Robert N, et al.
Front Oncol
. 2023 Dec;
13:1271847.
PMID: 38125947
Multiple myeloma (MM) is a hematological malignancy characterized by an abnormal clonal proliferation of malignant plasma cells. Despite the introduction of novel agents that have significantly improved clinical outcome, most...
3.
Chemlal D, Varlet E, Machura A, Ovejero S, Requirand G, Robert N, et al.
Leukemia
. 2023 Aug;
37(9):1925-1928.
PMID: 37532787
No abstract available.
4.
Ovejero S, Viziteu E, Dutrieux L, Devin J, Lin Y, Alaterre E, et al.
Front Immunol
. 2022 Dec;
13:983181.
PMID: 36569948
Multiple myeloma (MM) is a hematologic cancer characterized by accumulation of malignant plasma cells in the bone marrow. To date, no definitive cure exists for MM and resistance to current...
5.
Vlummens P, Verhulst S, de Veirman K, Maes A, Menu E, Moreaux J, et al.
Front Cell Dev Biol
. 2022 Jun;
10:879057.
PMID: 35757005
Multiple myeloma (MM) is an incurable clonal plasma cell malignancy. Subsets of patients have high-risk features linked with dismal outcome. Therefore, the need for effective therapeutic options remains high. Here,...
6.
Alaterre E, Ovejero S, Herviou L, de Boussac H, Papadopoulos G, Kulis M, et al.
Theranostics
. 2022 Feb;
12(4):1715-1729.
PMID: 35198065
Human multiple myeloma (MM) cell lines (HMCLs) have been widely used to understand the molecular processes that drive MM biology. Epigenetic modifications are involved in MM development, progression, and drug...
7.
de Boussac H, Bruyer A, Jourdan M, Maes A, Robert N, Gourzones C, et al.
Haematologica
. 2019 Jul;
105(3):784-795.
PMID: 31289205
Multiple myeloma (MM) account for approximately 10% of hematological malignancies and is the second most common hematological disorder. Kinases inhibitors are widely used and their efficiency for the treatment of...
8.
Jourdan M, de Boussac H, Viziteu E, Kassambara A, Moreaux J
J Vis Exp
. 2019 Feb;
(143).
PMID: 30735200
Plasma cells (PCs) secrete large amounts of antibodies and develop from B cells that have been activated. PCs are rare cells located in the bone marrow or mucosa and ensure...
9.
de Boussac H, Gondeau C, Briolotti P, Duret C, Treindl F, Romer M, et al.
Drug Metab Dispos
. 2017 Dec;
46(3):223-236.
PMID: 29269410
Growth factors have key roles in liver physiology and pathology, particularly by promoting cell proliferation and growth. Recently, it has been shown that in mouse hepatocytes, epidermal growth factor receptor...
10.
Despeyroux A, Duret C, Gondeau C, Perez-Gracia E, Chuttoo L, de Boussac H, et al.
J Tissue Eng Regen Med
. 2017 Nov;
12(4):1062-1073.
PMID: 29106037
Liver failure remains the leading cause of post-operative mortality after hepatectomy. This study investigated the effect of treatment with allogenic mesenchymal stem cells (MSCs) on survival and liver regeneration 48 ...